The role of cytokines in cancer cachexia
暂无分享,去创建一个
[1] B. Barton,et al. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. , 2001, Cytokine.
[2] Jiandie D. Lin,et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. , 2001, Molecular cell.
[3] M. Tisdale,et al. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y , 2001, Journal of neurochemistry.
[4] A. Liu,et al. [Cytokines in experimental cancer cachexia]. , 2001, Zhonghua zhong liu za zhi [Chinese journal of oncology].
[5] A. Więcek,et al. [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy]. , 2001, Polskie Archiwum Medycyny Wewnetrznej.
[6] P. Ghezzi,et al. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. , 2001, Cytokine.
[7] V. Almendro,et al. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. , 2001, Cancer letters.
[8] M. Piras,et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites , 2001, Journal of Molecular Medicine.
[9] T. Ogihara,et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice , 2001, Gene Therapy.
[10] R. Bellantone,et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[11] J. Belizário,et al. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia , 2001, British Journal of Cancer.
[12] J. Fischer,et al. The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. , 2001, Biochemical and biophysical research communications.
[13] M. Breslow,et al. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.
[14] G. Mantovani,et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites , 2000, Journal of Molecular Medicine.
[15] C. Plata-salamán. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. , 2000, Nutrition.
[16] V. Baracos. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. , 2000, Nutrition.
[17] K. Lundholm,et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. , 2000, Cancer research.
[18] C. Y. Wang,et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.
[19] R. Dunlop,et al. Cytokines and advanced cancer. , 2000, Journal of pain and symptom management.
[20] F. López‐Soriano,et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats , 2000, British Journal of Cancer.
[21] F. López‐Soriano,et al. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? , 2000, Biochemical and biophysical research communications.
[22] L. Tessitore,et al. Leptin expression in colorectal and breast cancer patients. , 2000, International journal of molecular medicine.
[23] B. Barton,et al. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[24] P. Widdowson,et al. Effect of cytokines on hypothalamic neuropeptide Y release in vitro , 2000, Peptides.
[25] K. Fearon,et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor , 2000, The British journal of surgery.
[26] N. Forsberg,et al. Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. , 2000, Cytokine.
[27] E. Bruera,et al. Potential novel uses of thalidomide: focus on palliative care. , 2000, Drugs.
[28] M. Tisdale,et al. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. , 1999, Cancer research.
[29] L. Tessitore,et al. Leptin and tumor growth in rats , 1999, International journal of cancer.
[30] M. Tisdale,et al. Catabolism of adipose tissue by a tumour‐produced lipid‐mobilising factor , 1999, International journal of cancer.
[31] O. Ishiko,et al. Lipolytic activity of anemia-inducing substance from tumor-bearing rabbits. , 1999, Nutrition and cancer.
[32] T. Ogihara,et al. Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model , 1999, Gene Therapy.
[33] F. López‐Soriano,et al. In the rat, tumor necrosis factor α administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine‐induced thermogenesis? , 1998, FEBS letters.
[34] N. Agell,et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. , 1998, Cancer letters.
[35] F. López‐Soriano,et al. Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model , 1998, FEBS letters.
[36] M. Tisdale,et al. Mechanism of muscle protein degradation induced by a cancer cachectic factor. , 1998, British Journal of Cancer.
[37] R. Schwartz,et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α , 1998 .
[38] M. Tisdale,et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. , 1998, Cancer research.
[39] F. López‐Soriano,et al. Catabolic proinflammatory cytokines. , 1998, Current opinion in clinical nutrition and metabolic care.
[40] R. Surwit,et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Faggioni,et al. Induction of UCP2 gene expression by LPS: a potential mechanism for increased thermogenesis during infection. , 1998, Biochemical and biophysical research communications.
[42] D. McMillan,et al. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. , 1998, Annals of surgery.
[43] P. Bijlenga,et al. Uncoupling Protein-3 Expression in Rodent Skeletal Muscle Is Modulated by Food Intake but Not by Changes in Environmental Temperature* , 1998, The Journal of Biological Chemistry.
[44] R. Schwartz,et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] O. Ishiko,et al. Mechanism of depletion of liver glycogen in cancer cachexia. , 1997, Biochemical and biophysical research communications.
[46] K. Nakao,et al. Cloning of rat uncoupling protein‐3 and uncoupling protein‐2 cDNAs: their gene expression in rats fed high‐fat diet , 1997, FEBS letters.
[47] B. Lowell,et al. The Human Uncoupling Protein-3 Gene , 1997, The Journal of Biological Chemistry.
[48] M. Tisdale,et al. Induction of muscle protein degradation by a tumour factor. , 1997, British Journal of Cancer.
[49] F. López‐Soriano,et al. The metabolic basis of cancer cachexia , 1997, Medicinal research reviews.
[50] O. Boss,et al. Tissue‐dependent upregulation of rat uncoupling protein‐2 expression in response to fasting or cold , 1997, FEBS letters.
[51] B. Lowell,et al. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. , 1997, Biochemical and biophysical research communications.
[52] O. Boss,et al. Uncoupling protein‐3: a new member of the mitochondrial carrier family with tissue‐specific expression , 1997, FEBS letters.
[53] L. Tartaglia,et al. Cloning and Characterization of an Uncoupling Protein Homolog: A Potential Molecular Mediator of Human Thermogenesis , 1997, Diabetes.
[54] H. Moshage. Cytokines and the hepatic acute phase response , 1997, The Journal of pathology.
[55] N. Rothwell,et al. Involvement of cytokines in cachexia induced by T-cell leukaemia in the rat. , 1997, European cytokine network.
[56] Christophe Fleury,et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia , 1997, Nature Genetics.
[57] V. Praloran,et al. Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignances , 1997, Leukemia.
[58] N. Agell,et al. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. , 1997, Biochemical and biophysical research communications.
[59] Dennis J. Rivet,et al. Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia , 1997, The Journal of experimental medicine.
[60] E. Wouters,et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. , 1997, Clinical science.
[61] A. De Luca,et al. Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. , 1997, The American journal of physiology.
[62] C. Plata-salamán,et al. Neuropeptide Y blocks and reverses interleukin-1β-induced anorexia in rats , 1996, Peptides.
[63] A. Nath,et al. Impairment by interleukin 1 beta and tumour necrosis factor alpha of the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis in cultured rat hepatocytes. , 1996, The Biochemical journal.
[64] J. Roder,et al. Physiological effects of CNTF-induced wasting. , 1996, Cytokine.
[65] H. Ishitsuka,et al. Murine interleukin‐12 prevents the development of cancer cachexia in a murine model , 1996, International journal of cancer.
[66] F. López‐Soriano,et al. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. , 1996, Trends in pharmacological sciences.
[67] S. Willatts,et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.
[68] J. Friedman,et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. , 1996, The Journal of clinical investigation.
[69] K. Fearon,et al. Characterization of a cancer cachectic factor , 1996, Nature.
[70] R. Henry,et al. The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.
[71] B. Spiegelman,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.
[72] C. Plata-salamán. Anorexia during acute and chronic disease. , 1996, Nutrition.
[73] N. Agell,et al. Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. , 1996, Cancer letters.
[74] M. Croce,et al. Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. , 1996, Cancer investigation.
[75] Y. le Maho,et al. Stimulation of brown adipose tissue activity in tumor-bearing rats. , 1995, Canadian journal of physiology and pharmacology.
[76] J. O'fallon,et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] L. Tessitore,et al. Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). , 1995, British Journal of Cancer.
[78] M. Muscaritoli,et al. Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. , 1995, Nutrition.
[79] C. Garcı́a-Martı́nez,et al. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). , 1995, Cancer letters.
[80] K. Grabstein,et al. Interleukin-15: a novel anabolic cytokine for skeletal muscle. , 1995, Endocrinology.
[81] M. Miyata,et al. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin‐6 , 1995, International journal of cancer.
[82] H. Ishitsuka,et al. Establishment and characterization of cachexia‐inducing and ‐non‐inducing clones of murine colon 26 carcinoma , 1995, International journal of cancer.
[83] C. Garcı́a-Martı́nez,et al. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. , 1995, Cancer letters.
[84] W. Rom,et al. Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.
[85] L. Tessitore,et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. , 1995, The Journal of clinical investigation.
[86] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[87] N. Agell,et al. Muscle wasting associated with cancer cachexia is linked to an important activation of the atp‐dependent ubiquitin‐mediated proteolysis , 1995, International journal of cancer.
[88] E. Opara,et al. Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. , 1995, Neuroreport.
[89] R. Wolfe,et al. Insulin-like growth factor—I and insulin reduce leucine flux and oxidation in conscious tumor necrosis factor-indused dogs1 , 1995 .
[90] K. Yasumoto,et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. , 1995, Cancer research.
[91] M. Burt,et al. Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. , 1995, Metabolism: clinical and experimental.
[92] C. Garcı́a-Martı́nez,et al. Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. , 1994, Cancer letters.
[93] M. Miyata,et al. Characterization of Mice Bearing Subclones of Colon 26 Adenocarcinoma Disqualifies Interleukin‐6 as the Sole Inducer of Cachexia , 1994, Japanese journal of cancer research : Gann.
[94] J. Blay,et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. , 1994, Blood.
[95] L. Tessitore,et al. Anti-tumour necrosis factor-α treatment interferes with changes in lipid metabolism in a tumour cachexia model , 1994 .
[96] J. Peters,et al. Proteasomes: protein degradation machines of the cell. , 1994, Trends in biochemical sciences.
[97] K. Feingold,et al. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. , 1994, Endocrinology.
[98] N. Agell,et al. Ubiquitin Gene Expression in Skeletal Muscle Is Increased by Tumor Necrosis Factor-α , 1994 .
[99] N. Agell,et al. Ubiquitin gene expression is increased in skeletal muscle of tumour‐bearing rats , 1994, FEBS letters.
[100] J. Gauldie,et al. The acute phase response. , 1994, Immunology today.
[101] C. Garcı́a-Martı́nez,et al. Interleukin-6 does not activate protein breakdown in rat skeletal muscle. , 1994, Cancer letters.
[102] J. Fischer,et al. Possible role of neuropeptide Y in experimental cancer anorexia. , 1994, Advances in experimental medicine and biology.
[103] J. Fischer,et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. , 1994, Life sciences.
[104] B. Spiegelman,et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. , 1994, Endocrinology.
[105] C. Balázs,et al. Immunological aspects of the effect of pentoxifylline (Trental) (a brief review). , 1994, Acta microbiologica et immunologica Hungarica.
[106] L. Tessitore,et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.
[107] R. Nordan,et al. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. , 1993, The Journal of clinical investigation.
[108] A. Cerami,et al. Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. , 1993, Cytokine.
[109] M. Llovera,et al. Effects of Tumor Necrosis Factor-α on Muscle-Protein Turnover in Female Wistar Rats , 1993 .
[110] G. Kaplan,et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.
[111] N. Agell,et al. Tumour necrosis factor‐α increases the ubiquitinization of rat skeletal muscle proteins , 1993 .
[112] G. Kaplan,et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.
[113] B. Spiegelman,et al. Through thick and thin: Wasting, obesity, and TNFα , 1993, Cell.
[114] M. Llovera,et al. Chronic tumour necrosis factor-alpha treatment modifies protein turnover in rat tissues. , 1993, Biochemistry and molecular biology international.
[115] S. Endres,et al. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. , 1993, International journal of immunopharmacology.
[116] J. Bag,et al. Expression of c‐jun/AP‐1 during myogenic differentiation in mouse C2C12 myoblasts , 1993, FEBS letters.
[117] S. Mori,et al. Leucine and manifestation of antitumor activity by valine-depleted amino acid imbalance. , 1993, Nutrition.
[118] Nancy Y. Ip,et al. The α component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development , 1993, Neuron.
[119] L. Tessitore,et al. Humoral mediation for cachexia in tumour-bearing rats. , 1993, British Journal of Cancer.
[120] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[121] C. Garcı́a-Martı́nez,et al. The role of cytokines in muscle wasting: Its relation with cancer cachexia , 1992, Medicinal research reviews.
[122] L. Tessitore,et al. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). , 1992, British Journal of Cancer.
[123] J. Tayek. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. , 1992, Journal of the American College of Nutrition.
[124] T. Borg,et al. Immunolocalization of ubiquitin conjugates at Z-bands and intercalated discs of rat cardiomyocytes in vitro and in vivo. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[125] W. Yasmineh,et al. Effect of Tumor Necrosis Factor on Enzymes of Gluconeogenesis in the Rat , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[126] L. Tartaglia,et al. Two TNF receptors. , 1992, Immunology today.
[127] W. Fiers,et al. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. , 1992, Endocrinology.
[128] C H Lang,et al. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.
[129] K. Abe,et al. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. , 1991, Cancer research.
[130] P. Pani,et al. Total and HDL cholesterol in human hematologic neoplasms. , 1991, International journal of hematology.
[131] J. Stephens,et al. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. , 1991, The Journal of biological chemistry.
[132] M. Tisdale,et al. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. , 1991, Cancer research.
[133] C. Cangiano,et al. Increased availability of tryptophan in brain as common pathogenic mechanism for anorexia associated with different diseases. , 1991, Nutrition.
[134] M. Rechsteiner. Natural substrates of the Ubiquitin proteolytic pathway , 1991, Cell.
[135] A. Billiau,et al. Severe cachexia in mice inoculated with interferon‐γ‐producing tumor cells , 1991 .
[136] J. Fischer,et al. Hyperammonemia and anorexia in Morris hepatoma-bearing rats , 1991, Physiology & Behavior.
[137] G. Wilding,et al. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. , 1991, Cancer research.
[138] W. Fiers,et al. Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor, interleukin 1, and interleukin 6 but not by interferon-alpha. , 1991, Cancer research.
[139] H. D. Mulligan,et al. Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. , 1991, British Journal of Cancer.
[140] G. Kaplan,et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.
[141] F. López‐Soriano,et al. The energy state of tumor-bearing rats. , 1991, The Journal of biological chemistry.
[142] S. Lowry. Cancer cachexia revisited: old problems and new perspectives. , 1991, European journal of cancer.
[143] D. Gandara,et al. Progress in the control of acute and delayed emesis induced by cisplatin. , 1991, European journal of cancer.
[144] K. Lundholm,et al. Elevated energy expenditure in cancer patients with solid tumours. , 1991, European journal of cancer.
[145] G. Opdenakker,et al. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.
[146] R. Krauss,et al. Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition. , 1990, Endocrinology.
[147] W. Fiers,et al. Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. , 1990, Cancer research.
[148] W. Mcbride,et al. Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. , 1990, The American journal of medicine.
[149] F. López‐Soriano,et al. The oxidation of leucine in tumour-bearing rats. , 1990, The Biochemical journal.
[150] H. Ishitsuka,et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.
[151] J. Patton,et al. Recombinant Tumor Necrosis Factor-α Chronically Administered in Rats: Lack of Cachectic Effect , 1990 .
[152] L. Giacomelli,et al. Plasma clearance of exogenous lipids in patients with malignant disease. , 1990, Nutrition.
[153] M. McNurlan,et al. Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. , 1990, Cancer research.
[154] M. Siimes,et al. Tumor necrosis factor in children with malignancies. , 1990, Cancer research.
[155] M. Buse,et al. Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase. , 1990, The Journal of clinical investigation.
[156] S. Fried,et al. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. , 1989, Journal of lipid research.
[157] N. Rothwell,et al. Increased brown adipose tissue activity in children with malignant disease. , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[158] M. Tisdale,et al. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. , 1989, Cancer research.
[159] M. Serio,et al. Multiple cytokines stimulate hepatic lipid synthesis in vivo. , 1989, Endocrinology.
[160] K. Yamaguchi,et al. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. , 1989, Biochemical and biophysical research communications.
[161] M. Serio,et al. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. , 1989, Endocrinology.
[162] J. Pomposelli,et al. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. , 1989, The Journal of clinical investigation.
[163] D. Brenner,et al. Prolonged activation of jun and collagenase genes by tumour necrosis factor-α , 1989, Nature.
[164] J. Norton,et al. Cachectin activity in the serum of cachectic, tumor-bearing rats. , 1989, Archives of surgery.
[165] D. Williamson,et al. Tumour necrosis factor alpha (cachectin) mimics some of the effects of tumour growth on the disposal of a [14C]lipid load in virgin, lactating and litter-removed rats. , 1988, The Biochemical journal.
[166] L. Moldawer,et al. Monocytic production and plasma bioactivities of interleukin‐1 and tumour necrosis factor in human cancer , 1988, European journal of clinical investigation.
[167] S. Mahony,et al. Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. , 1988, British Journal of Cancer.
[168] J. Norton,et al. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. , 1988, Cancer research.
[169] P. Kern. Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. , 1988, Journal of lipid research.
[170] J. Kuhn,et al. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. , 1988, Journal of the National Cancer Institute.
[171] A. Cerami,et al. Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.
[172] S. H. Socher,et al. Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice , 1988, The Journal of experimental medicine.
[173] D. Williamson,et al. Tissue-specific effects of rapid tumour growth on lipid metabolism in the rat during lactation and on litter removal. , 1988, The Biochemical journal.
[174] K. Kim,et al. Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and preadipocyte differentiation. , 1988, Molecular endocrinology.
[175] K. Tracey,et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation , 1988, The Journal of experimental medicine.
[176] P. Selby,et al. ENDOGENOUS TUMOUR NECROSIS FACTOR IN CANCER PATIENTS , 1988, The Lancet.
[177] B. Aggarwal,et al. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. , 1988, Cancer research.
[178] S. Enerbäck,et al. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. , 1988, The Biochemical journal.
[179] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[180] J. Gabrilove,et al. The acute metabolic effects of tumor necrosis factor administration in humans. , 1987, Archives of surgery.
[181] J. Tavernier,et al. EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER , 1987, The Lancet.
[182] J. Norton,et al. Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon. , 1987, Journal of the National Cancer Institute.
[183] R. Warren,et al. Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy. , 1987, The Journal of clinical investigation.
[184] F. López‐Soriano,et al. Blood amino acid compartmentation in mice bearing Lewis lung carcinoma. , 1987, Cancer research.
[185] L. F. Fajardo,et al. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. , 1987, Science.
[186] J. Norton,et al. Impact of insulin on doxorubicin-induced rat host toxicity and tumor regression. , 1987, Cancer research.
[187] A. Oliff,et al. Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.
[188] L. Moldawer,et al. Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. , 1987, Clinical physiology.
[189] J. Norton,et al. Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats. , 1987, The Journal of surgical research.
[190] K. Feingold,et al. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. , 1987, The Journal of clinical investigation.
[191] J. Tavernier,et al. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. , 1987, The Journal of biological chemistry.
[192] B. Camitta,et al. Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukemia. , 1987, JPEN. Journal of parenteral and enteral nutrition.
[193] M. Kawakami,et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. , 1987, Journal of biochemistry.
[194] L. Tessitore,et al. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. A model system for cancer cachexia. , 1987, The Biochemical journal.
[195] P. Pekala,et al. Regulation of lipoprotein lipase synthesis and 3T3-L1 adipocyte metabolism by recombinant interleukin 1. , 1986, Biochimica et biophysica acta.
[196] P. Scuderi,et al. RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS , 1986, The Lancet.
[197] A. Waage,et al. Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients , 1986, Scandinavian journal of immunology.
[198] P. Pekala,et al. Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor--the primary regulatory role of the hormone in 3T3-L1 adipocytes. , 1986, Archives of biochemistry and biophysics.
[199] B. Aggarwal,et al. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[200] R. Bergman,et al. Pathophysiology of malnutrition in the adult cancer patient , 1986, Cancer.
[201] N. Rothwell,et al. Brown adipose tissue and the response to overfeeding. , 1986, Biochemical Society transactions.
[202] B. Beutler,et al. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. , 1985, Journal of immunology.
[203] W. Dewys. Management of cancer cachexia. , 1985, Seminars in oncology.
[204] H. Holtmann,et al. CACHECTIN/TUMOUR-NECROSIS-FACTOR PRODUCTION BY CANCER PATIENTS , 1985, The Lancet.
[205] A. Varshavsky,et al. The ubiquitin system: functions and mechanisms , 1985 .
[206] B. Beutler,et al. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.
[207] P. Lazo. Tumour‐host metabolic interaction and cachexia , 1985, FEBS letters.
[208] R. Makuch,et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. , 1985, Cancer research.
[209] C. Hardy,et al. Cancer and malnutrition—A critical interaction: A review , 1985, American journal of hematology.
[210] S. Eisenberg,et al. High density lipoprotein metabolism. , 1984, Journal of lipid research.
[211] W. Mitch,et al. Specificity of the effects of leucine and its metabolites on protein degradation in skeletal muscle. , 1984, The Biochemical journal.
[212] M. Skinner,et al. Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Diseases , 1984, Scandinavian journal of immunology.
[213] P. Garlick,et al. Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. , 1984, Cancer research.
[214] A. Ciechanover,et al. The ubiquitin‐mediated proteolytic pathway and mechanisms of energy‐dependent intracellular protein degradation , 1984, Journal of cellular biochemistry.
[215] D. J. Millward,et al. Depressed protein synthesis is the dominant characteristic of muscle wasting and cachexia. , 1983, Clinical physiology.
[216] A. Cerami,et al. Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[217] D. Nicholls. The thermogenic mechanism of brown adipose tissue , 1983, Bioscience reports.
[218] M. Rennie,et al. Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. , 1982, Cancer research.
[219] G. Keusch,et al. Infection and diabetes: the case for glucose control. , 1982, The American journal of medicine.
[220] A. Goldberg,et al. Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? , 1982, The Journal of biological chemistry.
[221] A. Richmond,et al. Metabolic approaches to cancer cachexia. , 1982, Annual review of nutrition.
[222] M. Tee,et al. Leucine oxidation and protein degradation in the extensor digitorum longus and soleus of the tumor-bearing host. , 1981, Biochemical medicine.
[223] M. Brennan. Total parenteral nutrition in the cancer patient. , 1981, The New England journal of medicine.
[224] J. Mead,et al. Characterization of a lipid mobilizing factor from tumors. , 1981, Progress in lipid research.
[225] H. Okuda,et al. Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180. , 1981, Cancer research.
[226] M. Kutner,et al. Protein-calorie undernutrition in hospitalized cancer patients. , 1980, The American journal of medicine.
[227] A Ciechanover,et al. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[228] A. Reilley,et al. An investigation of the cause of death from cancer , 1980, Journal of surgical oncology.
[229] T. Scherstén,et al. Protein synthesis in liver tissue under the influence of a methylcholanthrene-induced sarcoma in mice. , 1979, Cancer research.
[230] J. Keilson,et al. Gluconeogenesis from alanine in patients with progressive malignant disease. , 1979, Cancer research.
[231] W. Dewys. Anorexia as a general effect of cancer , 1979, Cancer.
[232] R. Adams,et al. Principles of Neurology , 1996 .
[233] J. D. Davis,et al. A model for the control of ingestion. , 1977, Psychological review.
[234] E. Racker. Why do tumor cells have a high aerobic glycolysis? , 1976, Journal of cellular physiology.
[235] S. Adibi. Metabolism of branched-chain amino acids in altered nutrition. , 1976, Metabolism: clinical and experimental.
[236] E. Copeland,et al. Effect of Intravenous Hyperalimentation on Established Delayed Hypersensitivity in the Cancer Patient , 1976, Annals of surgery.
[237] M. Buse,et al. Leucine. A possible regulator of protein turnover in muscle. , 1975, The Journal of clinical investigation.
[238] A. Goldberg,et al. Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. , 1975, The Journal of biological chemistry.
[239] R. Albertini,et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. , 1968, Lancet.
[240] J. MacGee,et al. ALTERED CORTISOL METABOLISM IN ADVANCED CANCER AND OTHER TERMINAL ILLNESSES: EXCRETION OF 6-HYDROXYCORTISOL. , 1964, Metabolism: clinical and experimental.
[241] Foss Mv. CARDIAC ARREST AND ADRENALINE. , 1964 .
[242] J. Holland,et al. Effects of Krebs-2 carcinoma on the lipide metabolism of male Swiss mice. , 1962, Cancer research.
[243] A. Glicksman,et al. Diabetes and altered carbohydrate metabolism in patients with cancer , 1956, Cancer.
[244] R. J. Block,et al. Amino acid handbook , 1956 .
[245] S. Warren. THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .